NCT07391605

Descartes-08 in Autoantibody Myositis

A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Cartesian Therapeutics · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy, safety and tolerability of an autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA) in patients with autoantibody-mediated myositis, including antisynthetase syndrome (ASyS) and dermatomyositis (DM).

Conditions

• Antisynthetase Syndrome

Interventions

Type	Name	Description
DRUG	Descartes-08	Autologous T-cells expressing a chimeric antigen receptor (CAR) directed to B-Cell maturation antigen (BCMA)
OTHER	Placebo	Plasma-Lyte

Timeline

• Start date: 2026-06-30
• Primary completion: 2026-11-01
• Completion: 2027-05-01
• First posted: 2026-02-06
• Last updated: 2026-04-08

Regulatory

• FDA-regulated drug study